Navigation Links
Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) and the Company's clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Oncology (ASCO) in Chicago and the American Society of Gene Therapy (ASGT) in Seattle.

"We have a stronger than ever, advancing pipeline of first-in-class cancer therapies generating exciting data that could change the way cancer is treated and fulfill the promise of molecularly targeted cancer therapy," said Robert E. Sobol, M.D., senior vice president of Medical and Scientific Affairs at Introgen. "We have multiple Phase 3 programs either underway or planned with the goal of bringing these therapies to market to provide new treatments for widely underserved patient populations that are effective, generally well tolerated and can be easily combined and act synergistically with standard therapies by or before the end of this decade."

ASCO

-- Final results of a phase II trial of patients with extensive stage small cell lung cancer (ES-SCLC) immunized with wild type -p53 transduced dendritic cells after first-line chemotherapy, Abstract #3012: Poster presentation on Sun., June 3, from 2:00 - 6:00 p.m. in room S102a at McCormick Place, by lead author Alberto Chiappori, M.D., H. Lee Moffitt Cancer Center and Research Institute.

-- Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck, Abstract #6057: Poster presentation on Mon., June 4, from 1:00 - 5:00 p.m. at McCormick Place by lead author John Nemunaitis, M.D., Mary Crowley Medical Research Center and poster presentation by Robert Sobol, M.D., Introgen Therapeutics, Inc.

ASGT

-- Role of the Immune Sy
'"/>




Page: 1 2 3

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Genetic Analysis Systems Enter the Clinical Mainstream
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
9. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Composition Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy ... and Hydrostatic Weighing) - Global Analysis & Forecast to ... Market was pegged at $911.1 Million 2014 and is ... at a CAGR of 9.4% from 2014 to 2019. ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
(Date:7/30/2015)... 30, 2015 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the ... have him on Edwards, board as we pursue our focused ... and CEO.  "Bob has provided a valuable perspective to our ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... WARSAW, Ind., April 12, 2011 Zimmer Holdings, Inc. (NYSE: ... quarter 2011 sales and earnings conference call will be broadcast ... 8:00 a.m. Eastern Time.  A news release detailing the quarterly ... the morning of the conference call. The ...
... April 12, 2011 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical ... or the "Company"), a developer, manufacturer and distributor ... ("TCM") in China, today announced that its wholly ... has received official approval to produce water-based mixtures. ...
Cached Medicine Technology:Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results 2China Botanic Pharmaceutical Approved to Produce Water-Based Mixtures 2China Botanic Pharmaceutical Approved to Produce Water-Based Mixtures 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... New Energy ... District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. ... exciting and important day for the entire community as the culmination of months of ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... organic, natural, therapeutic-grade oils from ingredients sourced all over the world, then manufactured ... considerable effort, we have developed the highest-quality oils in the industry, which we ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Radiology ... Michael Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol ... and founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of ...
(Date:7/31/2015)... Baltimore, MD (PRWEB) , ... July 31, 2015 ... ... Lure Docs of All Types " from NBC talked about a woman’s unfortunate ... dermatology. He performed sclerotherapy on her face, which resulted in blistering, swelling, bruising, ...
(Date:7/31/2015)... ... ... “ Crack’em ” was featured on NewsWatch as part of its monthly Tech ... a technology expert and special reporter for NewsWatch, conducted the review and shared with ... be a very messy experience, especially when cracking eggs. Cracking an egg is easy, ...
Breaking Medicine News(10 mins):Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:Make Less Mess while Cooking with Crack’em 2
... , FRIDAY, April 20 (HealthDay News) -- Patients ... or pelvic surgery if they have open surgery rather than ... obstruction -- a blockage in the small intestines -- can ... tissue formation and is a common reason for emergency admission ...
... analyzing treatment decisions in late-stage amyotrophic lateral sclerosis (ALS) ... duration and quality of life in this progressively debilitating ... at the University of Pennsylvania found that waiting until ... not living long enough to experience the benefits. In ...
... HealthDay Reporter , FRIDAY, April 20 (HealthDay News) ... injuries with long-lasting damage in 2011 -- the highest number ... "major problem," a new report claims. The finding is ... for Catastrophic Sports Injury Research at the University of North ...
... A mysterious, difficult-to-diagnose, and potentially deadly disease that ... effectively if treatment is started within the first ... report by researchers from the Perelman School of ... analyzed 565 cases of this recently discovered paraneoplastic ...
... Could engineered human stem cells hold the key ... and Nanotechnology (IBN), the world,s first bioengineering and nanotechnology ... the innate ability to target tumor cells outside the ... on breast cancer cells, was recently published in leading ...
... , THURSDAY, April 19 (HealthDay News) -- There were 222 ... States last year, more than four times the usual annual ... had the most number of reported measles in the U.S. ... National Center for Immunization and Respiratory Disease at the U.S. ...
Cached Medicine News:Health News:Lower Risk for Bowel Obstruction With Less Invasive Surgery: Study 2Health News:ALS patients differ on treatment choices in later phases of disease 2Health News:'Catastrophic' Head Injuries to High School Football Players Rising 2Health News:'Catastrophic' Head Injuries to High School Football Players Rising 3Health News:Early treatment improves outcomes in rare, often undiagnosed form of encephalitis 2Health News:IBN discovers human neural stem cells with tumor targeting ability 2Health News:IBN discovers human neural stem cells with tumor targeting ability 3Health News:Measles Outbreaks in 2011 Were Worst in 15 Years: CDC 2
Hypervisor III Central Monitoring System...
For the critical care environment, telemetry, emergency room and other monitoring areas....
The CIC Pro Clinical Information Center brings together vital patient information from multiple monitoring devices....
... is a solution for hospitals, communicating ... signs monitoring. Waveform and numeric data ... simultaneous display of up to 32 ... trends are stored automatically. Alarms provide ...
Medicine Products: